ERBB2 and non-small cell lung carcinoma: Preclinical data indicate the hyper activation of EGFR, IGF-1R, and HER3 in NSCLC cell lines with acquired resistance to ceritinib [75], and an increase in phosphorylation of EGFR, HER2 [68], and IGF-1R in NSCLC cell lines with acquired resistance to alectinib.